Compare Medpace Holdings Inc (MEDP) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs AT&T Inc. — how do they compare? Medpace Holdings Inc trades at $610.04 (market cap $16.82B), while AT&T Inc. trades at $22.87 (market cap $170.42B). The key difference: AT&T Inc. is far larger — about 10.1× Medpace Holdings Inc's market cap, and AT&T Inc. pays a 4.46% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and AT&T Inc. for 118 Days on average.
| MEDP | T | |
|---|---|---|
Market Cap | $16.82B | $170.42B |
Volume | 223,093 | 50,780,036 |
Sector | Health | Media |
52-Week High | $630.19 | $29.10 |
52-Week Low | $393.42 | $20.49 |
Typical Hold Time | 14 Days | 118 Days |
Enterprise Value | $16.44B | $315.74B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
AT&T (T) trades at $24.48, up 0.2% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.2, 16.9% net margin, and consistent dividend payments. Revenue grew to $125.7B in 2025, while debt reduction and fiber expansion with Corning highlight strategic initiatives. Analyst consensus is mixed with 44% buy ratings and a $27.61 price target.
The outlook balances value appeal against competitive pressures. The low valuation and 4% yield attract income investors, but legacy revenue declines and high debt pose risks. Fiber investments and wireless growth offer upside, yet execution and market saturation remain challenges. The stock presents a dividend-income opportunity with moderate growth potential in a competitive telecom landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
